Treating ovarian cancer: New pathways through genetics

A new discovery that sheds light on the genetic make up of ovarian cancer cells could explain why some women survive longer than others with this deadly disease.

A multi-disciplinary team led by the Research Institute of the McGill University Health Centre (RI MUHC), in collaboration with the Lady Davis Institute of the Jewish General Hospital and the University of Montreal Hospital Research Centre, has identified genetic patterns in ovarian cancer tumours that help to differentiate patients based on the length of their survival after initial surgery. The study was published in the journal PLOS ONE.

“We discovered genetic differences in the tumours from ovarian cancer patients that relate to their short-term and overall response to standard treatment,” explained Dr. Patricia Tonin, the study's lead author and a cancer researcher at the RI MUHC and Associate Professor of the Department of Medicine at McGill University. “Using these genetic 'tools' to examine the tumours removed in the initial surgery, we may be able to offer alternative therapeutic options to women to improve their outcome.”

Each year 2,000 new cases of ovarian cancer are reported in Canada, and in 75 per cent of these cases the women die less than five years after their diagnosis. This study focused on the genetic analysis of high grade serous ovarian carcinomas (HGSC) in women from Quebec – the deadliest type of ovarian cancer which accounts for 90 per cent of deaths.

Almost all women with HGSC have mutations in the gene TP53, which is responsible for making the p53 protein. This gene is known as the “guardian of the genome” because of its role in regulating cell division and thus preventing cancer. Scientists already knew there were two different types of tumours, some with TP53 mutations that produce a mutant p53 protein and others without.

By uncovering the existence of genetic differences between the two types of HGSCs, the study reinforces the idea that there are biological differences in these cancers that can be related to the nature of the TP53 mutation and differences in genetic markers. The research team also confirmed that patient survival was longer in cases with the mutant p53 protein, compared to those that without the mutant protein.

“Biology is showing us which direction to take,” enthused Dr. Tonin. “This unique finding paves the way for identifying the pathways involved in cancer progression, leading to the development of alternative therapies and therefore helping to reduce morbidity and mortality in women fighting the disease”.

Click here to access the study online
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0045484
Funding
This work was funded by the Fonds de recherche du Québec-Santé (FRQS), the Terry Fox Research Institute (TFRI), Weekend to End Women's Cancer through the Lady Davis Institute for Medical Research at the Jewish General Hospital and the Canadian Institutes of Health Research (CIHR).

Research partners

The study “The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome” was co-authored by Paulina M Wojnarowicz, Karen Gambaro and Ashley H Birch of McGill University; Kathleen Klein Oros of the Lady Davis Institute, Jewish General Hospital; Michael CJ Quinn, Jason Madore and Manon de Ladurantaye of the University of Montreal Hospital Research Centre (CRCHUM), Institut du cancer de Montréal; Suzanna L Arcand of the Research Institute of the McGill University Health Centre (RI MUHC); Kurosh Rahimi of the CHUM; Diane M Provencher of CRCHUM and Université de Montréal; Anne-Marie Mes-Masson of CRCHUM and Université de Montréal; Celia MT Greenwood of the Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, and McGill University and Patricia N Tonin of the RI MUHC and McGill University.

Useful links

Research Institute of the MUHC: muhc.ca/research
McGill University Health Centre (MUHC): muhc.ca
McGill University: mcgill.ca
PLOS ONE: plosone.org
Media
Julie Robert
Communications – Research
Public Affairs & Strategic Planning
McGill University Health Centre
Phone: 514-934-1934 (ext. 71381)
julie.robert@muhc.mcgill.ca

Media Contact

Julie Robert EurekAlert!

More Information:

http://www.muhc.mcgill.ca

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors